On July 27, ReWalk Robotics Ltd. announced that it will release Q2 2015 financial results before the U.S. financial markets open on August 6. Larry Jasinski, Chief Executive Officer, and Kevin Hershberger, Chief Financial Officer, will conduct a conference call at 8:30 EDT. To join the call, dial (844) 423-9889 toll free from in the US or (716) 247-5804 from outside the US. From inside Israel you can join the call at 1-809-315362.
Mellanox Q2 Revenues Up 11.2%
Among the highlights of Mellanox July 23announcement was an 11.2% increase in revenues compared to the previous quarter.
Rewalk Robotics upgraded from sell to hold rating by analysts at Zacks July 8
Analysts at Zacks upgraded their ratings of Rewalk Robotics (NASDAQ:RWLK) on Wednesday, July 8. For details...
Mellanox to Release Second Quarter 2015 Financial Results on July 22
On July 2, Mellanox Technologies announced that it would release Q2 2015 financial results after the market closes on July 22. After the release, Mellanox will conduct a conference call at 2 p.m. Pacific Time (midnight in Israel). Dial +1-785-424-1666 approximately ten minutes before the start time to listen in.
Viora acknowledged patent infringement in settlement with Syneron and agrees to pay royalties for 12 years
On June 24, an announcement was released via PRNewswire that Syneron and Viora announced a settlement agreement of business and patent litigations. As part of the agreement, Viora iora acknowledged that its Reaction product infringes Syneron's U.S. patent No. 6,662,054 and agreed to pay royalties of 7.5% to 15% for 12 years, depending on the number of relevant systems sold by Viora in the U.S. For details...
In an earlier announcement released via PRNewswire, Syneron Medical reported revenue of $63.4 for Q1 2015, which was an increase of 12% over the previous year and 17% in constant currency. For details...
Rewalk facing bureaucratic hurdles in Japan after success in Europe and the US
Huffpost Healthy Living report on May 13 that Rewalk is facing bureaucratic difficulties in Japan. The article was very positive about Rewalk's revolutionary technology that enables paraplegics to walk and noted that Japanese drug approvals tend to take longer than in the U.S. and Europe. For details...
Q1 2015 earnings up 10.6% at Lumenis after accounting for currency fluctuations
In May, the Haaretz newspaper reported that Lumenis earnings increased 4.1% over the comparable 2014 quarter and 10.6% after accounting for currency fluctuations. For details...